An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1) and Expansion Cohort in Patients with Waldenstrom Macroglobulinemia (CLOVER-WaM)
Clinical Trial Grant
Awarded By
Cellectar Biosciences, Inc.
Start Date
March 9, 2023
End Date
December 11, 2025
Awarded By
Cellectar Biosciences, Inc.
Start Date
March 9, 2023
End Date
December 11, 2025